* Says exercised its option to sign a licensing agreement
with Swedish biotech company Affibody AB for the development of
novel treatments for inflammatory diseases where interleukin-1
(IL-1) is involved
Source text for Eikon:
Further company coverage:
(Stockholm Newsroom)
Read more
No comments:
Post a Comment